Association between Severity of Cannabis Dependence and Depression

Karina Karolina Kedzior, Mathew Martin-Iverson
DOI: 10.4236/psych.2010.14031                

Abstract

Objective. The aim of the current study was to investigate the relationship between self-reported severity of cannabis dependence and symptoms of depression. Method. The lifetime diagnoses of depression and cannabis misuse (abuse and/or dependence) were obtained from 50 participants recruited from the general community, using a self-completed diagnostic interview (CIDI-Auto 2.1). The lifetime severity of cannabis dependence was established using a standard questionnaire, Severity of Dependence Scale (SDS). Results. Of the 19 participants with mental illness diagnoses, 14 (74%) reported depression symptoms. The 14 participants with depression diagnoses had significantly more cannabis misuse diagnoses and significantly higher SDS scores compared to those without mental illness diagnoses (N = 31). SDS scores significantly predicted presence or absence of CIDI depression diagnoses with a 69% overall rate of cor-rect predictions. As SDS scores increased the odds of classification into depressed versus non-depressed groups was 1.3 (95% C.I. 1.02-1.57). Conclusion. The presence of lifetime depression symptoms is associated with higher lifetime severity of cannabis dependence and more lifetime cannabis misuse symptoms in otherwise healthy research vol-unteers.

Keywords

Severity of Cannabis Dependence, Depression, CIDI-Auto 2.1, SDS

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	H. Verdoux, “Cannabis and psychosis proneness,” In D. Castle and R. Murray, Eds., Marijuana and Madness: Psychiatry and Neurobiology, Cambridge University Press, New York, 2004, pp. 75-88.
[2]	L. Degenhardt, W. Hall, M. Lynskey, C. Coffey and G. Patton, “The Association between Cannabis Use and Depression: A Review of the Evidence,” In: D. Castle and R. Murray, Eds., Marijuana and Madness: Psychiatry and Neurobiology, Cambridge University Press, New York, 2004, pp. 54-74.
[3]	American Psychiatric Association, “Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),” American Psychiatric Association, 1994.
[4]	K. Kedzior and M. Martin-Iverson, “Chronic Cannabis Use is Associated with Attention-Modulated Reduction in Prepulse Inhibition of the Startle Reflex in Healthy Humans,” Journal of Psychopharmacology, Vol. 20, No. 4, 2006, pp. 471-484.
[5]	World Health Organi-zation, “Composite International Diagnostic Interview (CIDI), Version 2.1,” World Health Organisation, 1997.
[6]	M. Gos-sop, S. Darke, P. Griffiths, J. Hando, B. Powis, W. Hall and J. Strang, “The Severity of Dependence Scale (SDS): Psychometric Properties of the SDS in English and Australian Samples of Heroin, Cocaine and Amphetamine Users,” Addiction, Vol. 90, 1995, pp. 607-614.
[7]	K. Kedzior, J. Badcock and M. Mar-tin-Iverson, “Validity and Consistency of Self-Reports Regard-ing Substance Use in General Research Volunteers, Including Regular Cannabis Users and Schizophrenia Patients,” Substance Use and Misuse, Vol. 41, No. 5, 2006, pp. 743-750.
[8]	C. Ferri, J. Marsden, M. de Araujo, R. Laranjeira and M. Gossop, “Validity and Reliability of the Severity of Dependence Scale (SDS) in a Brazilian Sample of Drug Users,” Drug & Alcohol Review, Vol. 19, No. 4, 2000, pp. 451-455.
[9]	M. Gossop, D. Best, J. Marsden and J. Strang, “Test-Retest Reliability of the Severity of Dependence Scale (Comment),” Addiction, Vol. 92, No. 3, 1997, pp. 353.
[10]	G. Martin, J. Copeland, P. Gates and S. Gilmour, “The Severity of Dependence Scale (SDS) in an Adolescent Population of Cannabis Users: Reliability, Validity and Diagnostic Cut-Off,” Drug and Alcohol Dependence, Vol. 83, No. 1, 2006, pp. 90-93.
[11]	H.-U. Wittchen, “Reliability and Validity Studies of the WHO—Composite International Diagnostic Interview (CIDI): A Critical Review,” Journal of Psychiatric Research, Vol. 28, No. 1, 1994, pp. 57-84.
[12]	G. Andrews and L. Peters, “The Psychometric Properties of the Composite International Diagnostic Interview,” Social Psychiatry & Psychiatric Epidemiology, Vol. 33, No. 2, 1998, pp. 80-88.
[13]	K. Kedzior and M. Martin-Iverson, “Concurrent Validity of Cannabis Misuse Diagnoses on CIDI-Auto 2.1 in Low-Level Cannabis Users from the General Population,” Australian Journal of Psychology, Vol. 59, No. 3, 2007, pp. 169-175.
[14]	S. Bagley, H. White and B. Golomb, “Logistic Regression in the Medical Literature: Standards for Use and Reporting, with Particular Attention to One Medical Domain,” Journal of Clinical Epidemiology, Vol. 54, No. 10, 2001, pp. 979-985.
[15]	R. Pertwee and R. Ross, “Cannabinoid Receptors and their Ligands,” Prostaglandins Leukotrienes & Essential Fatty Acids, Vol. 66, No. 2-3, 2002, pp. 101-121.
[16]	T. Moore, S. Zammit, A. Lingford-Hughes, T. Barnes, P. Jones, M. Burke and G. Lewis, “Cannabis Use and Risk of Psychotic or Affective Mental Health Outcomes: A Systematic Review,” Lancet, Vol. 370, No. 9584, 2007, pp. 319-328.